Inactive Instrument

Axovant Sciences Ltd Stock Nyse

AXON

BMG0750W1047

Latest news about Axovant Sciences Ltd

Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from S&P TMI Index	23-03-27	CI
Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from NASDAQ Composite Index	23-03-22	CI
Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Sio Gene Therapies Board Approves Plan of Liquidation, Dissolution; Shares Rise After Hours	22-12-14	MT
Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10	CI
Sio Gene Therapies Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11	CI
Sio Gene Therapies Inc.(NasdaqGS:SIOX) dropped from S&P Global BMI Index	22-06-20	CI
Sio Gene Therapies Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-14	CI
Sio Gene Therapies Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-06-14	CI
Top Premarket Decliners	22-04-28	MT
HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy	22-04-28	MT
Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80	22-04-28	MT
Sio Gene Therapies to Explore and Review A Range of Strategic Alternatives Focused on Maximizing Stockholder Value	22-04-26	CI
Sio Gene Therapies Receives Nasdaq Listing Noncompliance Notice Over Minimum Closing Price	22-03-18	MT
Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-11	CI

More news

Analyst Recommendations on Axovant Sciences Ltd

HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy	22-04-28	MT
Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80	22-04-28	MT
Cantor Adjusts Sio Gene Therapies Price Target to $3 From $8, Maintains Overweight Rating	22-02-01	MT
HC Wainwright Adjusts Price Target on Sio Gene Therapies to $7 From $10, Reiterates Buy Rating	22-02-01	MT
SVB Leerink Downgrades Sio Gene Therapies to Market Perform From Outperform, Adjusts Price Target to $1 From $6	22-02-01	MT

More recommendations

Press releases Axovant Sciences Ltd

Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share	Feb. 02	GL
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share	Feb. 02	AQ
SIO GENE THERAPIES INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	23-04-06	AQ
Sio Gene Therapies : Failure to Satisfy Listing Rule - Form 8-K	23-03-15	PU
SIO GENE THERAPIES INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-03-15	AQ

More press releases

Managers and Directors - Axovant Sciences Ltd

Managers	Title	Age	Since
David Nassif CEO	Chief Executive Officer	70	19-06-30
Raquel Crystal COO	Chief Operating Officer	-	-

Members of the board	Title	Age	Since
David Nassif CEO	Chief Executive Officer	70	19-06-30

More insiders

Sio Gene Therapies Inc. was a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The Company has not generated any revenue.

Sector

More about the company